Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome.

Transplantation and cellular therapy·2026
Same author

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.

Leukemia·2026
Same author

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026
Same author

Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey.

Transfusion·2026
Same author

Efficacy of hypomethylating agents in combination with venetoclax in relapsed/refractory acute myeloid leukemia: A systematic review and meta-analysis.

Leukemia research·2026
Same author

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Polo-like kinases in AML.

Tobias Berg, Gesine Bug, Oliver G Ottmann

    Expert Opinion on Investigational Drugs
    |June 7, 2012
    PubMed
    Summary
    This summary is machine-generated.

    New cancer therapies targeting the cell cycle, specifically Polo-like kinase 1 (Plk1) inhibitors, show promise for treating leukemia and solid tumors. Research highlights the role of Plk1 and Plk2 in acute myeloid leukemia (AML) treatment strategies.

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Identification of Kinase-substrate Pairs Using High Throughput Screening
    11:13

    Identification of Kinase-substrate Pairs Using High Throughput Screening

    Published on: August 29, 2015

    Related Experiment Videos

    Last Updated: May 21, 2026

    A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
    14:34

    A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

    Published on: April 3, 2026

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Identification of Kinase-substrate Pairs Using High Throughput Screening
    11:13

    Identification of Kinase-substrate Pairs Using High Throughput Screening

    Published on: August 29, 2015

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Therapeutics

    Background:

    • The cell cycle is a critical target for novel cancer therapies.
    • Polo-like kinase 1 (Plk1) is a key regulator of mitosis and a promising target for cancer drug development.
    • Numerous clinical trials are investigating Plk1 inhibitors for solid tumors and leukemia.

    Discussion:

    • This review focuses on the roles of Plk1 and the potential tumor suppressor Plk2 in acute myeloid leukemia (AML).
    • Most cancers exhibit a dependency on Plk1, making it an attractive therapeutic target.
    • Understanding Plk1 and Plk2 functions is crucial for developing effective AML treatments.

    Key Insights:

    • Plk1 inhibitors are being evaluated in clinical trials for various cancers, including leukemia.
    • Plk1's essential role in mitosis makes it a vulnerability in many cancer types.
    • Plk2 may function as a tumor suppressor, offering additional therapeutic avenues in AML.

    Outlook:

    • Further research into Plk1 and Plk2 pathways could lead to more targeted and effective AML therapies.
    • The development of Plk1 inhibitors represents a significant advancement in cancer treatment strategies.
    • Investigating the interplay between Plk1 and Plk2 may unlock new therapeutic combinations for hematological malignancies.